Shire to buy rare-disease drugmaker NPS Pharmaceuticals for US$5.2b
Deal comes before NPS learns whether its Natpara medicine to treat hypoparathyroidism wins approval from the US FDA
London
SHIRE plc, the drugmaker seeking to boost growth after its proposed sale to AbbVie Inc collapsed, agreed to buy NPS Pharmaceuticals Inc for about US$5.2 billion to add medicines used to treat rare diseases.
Shire will pay US$46 a share in cash, the Dublin-based company said on Sunday in a statement. That's a 9.8 per cent premium to NPS's closing price on Jan 9 and more than 50 per cent higher than its close on Dec 16, before news broke of Shire's interest. The deal has been approved by both companies' boards.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Sheng Siong Q1 net profit up 9.3% on higher revenue
Nestle sales growth sputters on US slump, vitamin snags
Hermes Q1 sales jump 17% on strong China demand
Cordlife’s independent auditor to retire after issuing disclaimer of opinion on FY2023 financials
Cutting the cord?: Events leading up to Cordlife’s MOH suspension and arrests of its directors, ex-group CEO
Cordlife customers push for legal action